You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Claims for Patent: 10,479,868

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,479,868

Title:	Polymeric stabilizing formulations
Abstract:	The present invention provides compositions of a therapeutic agent and a polymeric stabilizing agent for stabilizing the reservoir of an implantable drug delivery system. The present invention also includes an implantable drug delivery system incorporating the composition of the present invention, as well as methods of treating diabetes using the compositions and implantable drug delivery system of the present invention.
Inventor(s):	Mendelsohn; Adam (Emeryville, CA), Duong; Au (Emeryville, CA), Fischer; Kathleen (Emeryville, CA), Roorda; Wouter (Emeryville, CA)
Assignee:	NANO PRECISION MEDICAL, INC. (Emeryville, CA)
Application Number:	15/508,572
Patent Claims:	1. A pharmaceutical composition comprising: a therapeutic agent, which therapeutic agent is a peptide, together with a polymeric stabilizing agent comprising a polymer having a plurality of stabilizing groups, wherein the polymer is a dendritic polymer or is a crossed-linked polymer, wherein said pharmaceutical composition is disposed within a reservoir of a capsule having a nanoporous membrane with a plurality of pores, the capsule configured for implantation; and the polymeric stabilizing agent comprising a polymer having a plurality of stabilizing groups having molecular dimensions larger than the pore size of the nanoporous membrane, wherein the release of the polymeric stabilizing agent from the reservoir is substantially prevented; and wherein the nanoporous membrane is a diffusion pathway out of the reservoir for the therapeutic agent. 2. The composition of claim 1, wherein the therapeutic agent is selected from the group consisting of beta-glucocerobrosidase, interferon alpha, interferon beta, agasidase alpha, agasidase beta, exenatide, nutropin/somatropin, factor VIII, fondaparinux, aldesleukinand, risperidone, forigerimod, NP fusion proteins, IL-12, a melanocyte stimulating hormone, and bapineuzumab. 3. The composition of claim 1, wherein the therapeutic agent is selected from the group consisting of exenatide, octreotide and fluphenazine. 4. The composition of claim 1, wherein the therapeutic agent comprises exenatide. 5. The composition of claim 1, wherein the polymer is a dendritic polymer. 6. The composition of claim 1, wherein the polymer is a poly(amidoamine) dendrimer having a plurality of end groups, wherein the plurality of end groups comprise at least one member selected from the group consisting of the acid groups, the base groups, alkyl, hydroxyalkyl, amidoethanol, amidoethylethanolamine, ethylenediamine, sodium carboxylate, succinamic acid, trimethoxysilyl, tris(hydroxymethyl)amidomethane, and 3-carbomethoxypyrrolidinone. 7. The composition of claim 6, wherein the end groups of the poly(amidoamine) dendrimer comprise sodium carboxylate. 8. The composition of claim 1, wherein each stabilizing group is independently selected from the group consisting of an acid group, a base group, an anti-oxidant, an anti-microbial, an anti-biotic, a protein clustering agent, and a protein declustering agent. 9. The composition of claim 1, wherein each stabilizing group is independently selected from the group consisting of an acid group and a base group. 10. The composition of claim 9, wherein the polymer is an acidic polymer selected from the group consisting of polyacrylic acid, polymethacrylic acid, polystyrene sulfonic acid, polyvinyl sulfonic acid, polyvinyl phosphonic acid and polystyrene phosphonic acid. 11. The composition of claim 10, wherein the polymer is crossed-linked. 12. The composition of claim 11, wherein the polymer is polyacrylic acid. 13. The composition of claim 11, wherein the polymer is polymethacrylic acid. 14. The composition of claim 9, wherein the acid groups are selected from the group consisting of carboxylic acid, amino acid, thiol, and phenol. 15. The composition of claim 9, wherein the acid groups are carboxylic acids. 16. The composition of claim 9, wherein the base groups are selected from the group consisting of hydroxy, cyano, amine and carboxylate. 17. The composition of claim 9, wherein the base groups are amines. 18. The composition of claim 1, wherein the polymer has a molecular diameter of at least 3 nm. 19. The composition of claim 1, wherein the polymer has a molecular diameter of at least 5 nm. 20. The composition of claim 1, wherein the pH of the composition is from about 3 to 7. 21. The composition of claim 1, wherein the pH of the composition is from about 4 to about 6. 22. The composition of claim 1, wherein the implantable drug delivery device contains a second membrane. 23. The composition of claim 22, wherein the second membrane provides a diffusion pathway for the therapeutic agent. 24. The composition of claim 22, wherein only one membrane provides a diffusion pathway for the therapeutic agent. 25. A method of treating a disease in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 1 comprising a therapeutic agent and a polymer functionalized with a plurality of stabilizing, thereby treating the disease. 26. The method of claim 25, wherein the disease is type 2 diabetes. 27. The method of claim 25, wherein the disease is type 1 diabetes. 28. The method of claim 25, wherein the therapeutic agent is exenatide. 29. The method of claim 28, wherein the mean steady-state plasma concentration of exenatide is 170 pg/ml to 600 pg/ml. 30. The method of claim 28, wherein the mean steady state plasma concentration of exenatide is 170 pg/ml to 350 pg/ml. 31. The method of claim 28, wherein the mean steady state plasma concentration of exenatide is 170 pg/ml to 290 pg/ml.

Details for Patent 10,479,868

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	June 23, 1987	⤷ Subscribe	2034-09-04
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	October 16, 1986	⤷ Subscribe	2034-09-04
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	February 04, 1999	⤷ Subscribe	2034-09-04
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	October 08, 1996	⤷ Subscribe	2034-09-04
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	August 29, 2000	⤷ Subscribe	2034-09-04
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	January 16, 2007	⤷ Subscribe	2034-09-04
Ferring Pharmaceuticals Inc.	ZOMACTON	somatropin	For Injection	019774	May 25, 1995	⤷ Subscribe	2034-09-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.